title: [French recommendations for invasive cervix cancer management during pregnancy on the behalf of the Société française d'oncologie gynécologique, the Société française de chirurgie pelvienne and the Collège national des gynécologues et obstétriciens français].
authors.affiliation: Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif, France. philippe.morice@igr.fr
authors.forename: P
authors.initials: P
authors.lastname: Morice
authors.forename: F
authors.initials: F
authors.lastname: Narducci
authors.forename: P
authors.initials: P
authors.lastname: Mathevet
authors.forename: H
authors.initials: H
authors.lastname: Marret
authors.forename: E
authors.initials: E
authors.lastname: Daraï
authors.forename: D
authors.initials: D
authors.lastname: Querleu
mesh_terms: D000028:Abortion, Induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005602:France; D006801:Humans; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011878:Radiotherapy / Q000009:adverse effects; D012955:Societies, Medical; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents